Doses actually delivered fell further to 54%–96% for oxaliplatin, 61%–88% for irinotecan, 0–92% for 5-FU bolus, and 63%–98% 5-FU continuous injection.
Despite the variations in dosing, reduced doses of FOLFIRINOX were associated with a slightly but not significantly higher objective response rate: 33.8% vs 28.2% for standard dosing . The incidence of febrile neutropenia was significantly lower in the reduced-dose groups: 5.5% with modified FOLFIRINOX vs 11.6% with standard .Although the study supports reduced-dose regimens, it also shows that there is"still no consensus" on appropriate dose modification, the authors said."The best dose modification protocol" remains to be determined and standardized for metastatic pancreatic cancer.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: